


Infertility Prevention Project Region II

May 13, 2009
New York City, New York

Steven J. Shapiro
Infertility Prevention Project Coordinator
CDC/NCHHSTP/DSTDP/PTB

Disclaimer: The findings and conclusions in this presentation are those of the author and do not necessarily represent the views of the Centers for Disease Control and Prevention.




Topics

National Infertility Prevention Project:

- Budget and Funding
- Division Strategic Goals
- Priority Activities
- Gonorrhea
- Performance Measures
 - CSPS
 - Infrastructure
 - NCQA and HEDIS





Strategic Goals

- Division of STD Prevention Strategic Plan October 2008
 - Prevent STD-related infertility
 - » Screening and Treatment; Partner Services
 - Prevent adverse outcomes of pregnancy
 - Prevent STD-related cancers
 - Prevent STD-related HIV transmission and acquisition
 - Strengthen STD prevention capacity and infrastructure
 - Reduce STD health disparities
 - Address effects of social and economic determinants and costs of STDs and associated *sequelae* among specific populations



Infrastructure Funding and Activities CDC-OPA IAA


- Coordinate Regional Meetings
 - Assure Equal Partnership
- Regional IPP Plan
- Conduct Site Visits
- Support National CT Prevention Activities
- Evaluate and Disseminate Data
- Data Quality Assurance
- Collaboration Special Projects
- Infrastructure Performance Measures
- Data Management
 - Collection
 - Quality Assurance
 - Analysis
 - Dissemination
- Attend Regional Coordinators Meetings





Project Area Funding and Activities CSPS IPP 09-902


- Ensure CT and GC Screening and Treatment
- Support Lab Testing
- Ensure Collection and Reporting of all core CDC data elements
- Provide Program Management
- Ensure Provider Training
- Grant Development
- Use Data to plan programs
 - Prevalence Monitoring
 - Surveillance
 - Performance Measures
- 50% Rule
- Male Screening
 - Up to 15% of IPP funds
- Targeted GC Screening
 - Up to 10% of IPP funds
 - GC Burden Calculation

















Resistance to Cephalosporins

- Oral Cephalosporins (Cefixime et al)
 - » 2% Treatment Failure
 - » Increasing MICs since 2003
 - » Increasing number of GC strains with decreased susceptibility
- Injectable Cephalosporins (Ceftriaxone)
 - » No documented treatment failures to date
 - » Increasing MICs since 2003
 - » Recommended treatment doses increasing



Past and Future

- Penicillins (larger and larger doses)
- Tetracyclines
- Spectinomycins
- Fluoroquinolones
- Oral Cephalosporins
- Injectable Cephalosporins
- Penems
- New Drugs?



Performance Measures

- CSPS Project started 1999
- Pilot project 2001
- Set of 12 measures 2005
 - » Timeliness of Treatment CT and GC in FP clinics
 - » STD Clinics added 2008
 - » GC Interviews modified 2009
- Infrastructure Performance Measures
 - » Among clients attending family planning clinics, the number of women screened for chlamydia, stratified by age.
 - » Screening coverage estimate among sexually active 15-19 year old women in FP clinics



Performance Measure Data

Timeliness of Treatment for CT (14 Days)

Prevalence Monitoring Family Planning Sites

	2005	2006	2007	2008
Region II 14 Days	0.35 (0.16-0.83)	0.62 (0.20-0.80)	0.51 (0.20-0.87)	0.50 (0.10-0.88)
National 14 Days	0.62	0.66	0.64	0.64

Performance Measure Data

Timeliness of Treatment for GC (14 Days)

Prevalence Monitoring Family Planning Sites

	2005	2006	2007	2008
Region II 14 Days	0.51 (0.00-0.74)	0.62 (0.00-0.74)	0.53 (0.00-0.84)	0.49 (0.00-0.85)
National 14 Days	0.61	0.67	0.64	0.64

Performance Measure Data


Timeliness of Treatment CT and GC (14 Days)

STD Sites- 2007 and 2008

	Chlamydia 2007	Chlamydia 2008	Gonorrhea 2007	Gonorrhea 2008
Region II 14 Days	0.66 (0.47-0.86)	0.69 (0.42-0.87)	0.74 (0.63-0.91)	0.66 (0.59-0.90)
National 14 Days	0.69	0.72	0.70	0.73

Performance Measures Gonorrhea Interviews

- **Old Measure:** Proportion of "priority" gonorrhea cases interviewed within 7, 14, and 30 days from date of specimen collection (2005-2008).
 - Programs receiving SE funds were not required to submit data for this measure.
- **New Measure:** Proportion of all gonorrhea cases interviewed within 7, 14, and 30 days from date of specimen collection.
 - HMA programs receiving SE funds are not required to submit data for this measure; non-HMAs receiving SE funds ARE required to submit data.



Infrastructure Performance Measures Estimated Screening Coverage (%) Females 15-19 years old

Region	2005	2006	2007	2008
I	36	38	43	46
II	46	46	50	53
III	50	52	51	53
IV	53	53	46	50
V	47	47	47	No Data
VI	56	55	58	No Data
VII	59	54	55	57
VIII	40	41	40	No Data
IX	55	60	35	No Data
X	34	35	38	No Data
National	50	50	51	N/A






Figure. Percentage of sexually active female enrollees aged 16-25 years who were screened for chlamydia, by health plan type and year – Healthcare Effectiveness Data and Information Set (HEDIS), 2000-2007

Year	Medicaid (%)	Commercial (%)
2000	32	25
2001	35	28
2002	38	30
2003	40	32
2004	42	35
2005	45	38
2006	48	40
2007	48	38



Infrastructure Performance Measures
Proportion of Tests
Females 15-24 years of age (%)

Region	2005	2006	2007	2008
I	61	62	61	64
II	62	63	64	63
III	67	72	68	70
IV	73	65	63	62
V	73	71	69	No data
VI	67	66	65	No data
VII	74	72	72	77
VIII	74	72	72	No data
IX	63	66	64	No data
X	81	78	74	No data
National	70	69	67	N/A



Questions?

